Enhancement of neutrophil antimicrobial activity by the breast cancer drug tamoxifen
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
Tags: breast cancer, estrogen modulator, estrogen receptor (ER) antagonist, prodrug, Soltamox®
BASi Method Number SAP.1617
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
